All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
471 matching companies
Signed a next-generation oral peptide co-development agreement with D&D explicitly including macrocyclic peptides. Its role is AI design; independent ownership of a disclosed clinical drug has not been established.
The company disclosed a patent for an oral semaglutide nanoparticle formulation. This is a noncyclic peptide delivery reference, not clinical validation for cyclic peptides.
The website separately describes H1K, an oral anti-obesity candidate, and ESAIDD cyclic peptide discovery. This review could not confirm that H1K is cyclic or has human results.
Co-commercializes approved LINZESS and holds regional rights, alongside oral peptide discovery through Nimble. ABBV-859 is in Phase 1; its exact structure and mapping to Nimble assets remain unconfirmed.
On 2026-10-22, the company announced a proposed acquisition of PepStar's HCXT-2001 oral macrocyclic peptide program. Its Q3 announcement confirms Phase 1; closing conditions remain outstanding.
Counterparty for the HCXT-2001 transaction. Its role is recorded separately from Gilead's; the shared candidate is not counted as two independent drugs. The relationship between the Chinese sponsor and English legal entity requires confirmation.
Uses AI to design oral IL-17A/F inhibitors. The company describes fully synthetic, compact cyclic peptidomimetics containing nonnatural amino acids.
A September 2026 company announcement states that an unnamed MSD candidate using its oral technology entered Phase 1. The candidate structure is not disclosed, so it cannot be classified as a cyclic peptide.
Soteria provides protective excipients, Phloral provides targeted release, and UTAC provides active transport of macromolecules. Cyclic peptide applications require separate validation.
The Novo collaboration uses gastrointestinal tissue screening and formulation platforms to develop oral biologics. Specific drugs and cyclic peptide structures have not been disclosed.
Peptelligence previously conducted feasibility studies with Ferring to convert injectable peptides into oral formulations. It is retained as a historical delivery approach; current operations and ownership require verification.
EB613 is oral PTH(1-34), with disclosed clinical results and new-formulation bridging data and a planned Phase 3 program. Human evidence for this linear peptide is used only as a platform reference.
RaniPill is a swallowable robotic capsule. RT-101 octreotide is a historical human development program whose current activity is unconfirmed, recorded separately from conventional intestinal permeation enhancement.
NEORAL cyclosporine is a classic benchmark for oral cyclic peptides and microemulsion preconcentrates; it should not be assumed bioequivalent to Sandimmune.
LINZESS (linaclotide) is an oral peptide with multiple disulfide bonds and a GC-C agonist acting locally in the gastrointestinal tract. Systemic bioavailability is not the primary success criterion.
TRULANCE (plecanatide) is an oral disulfide-constrained peptide and GC-C agonist acting locally in the gastrointestinal tract. Regional status is based on the Canadian product monograph reviewed.
Swallowed DDAVP desmopressin tablets are a classic oral disulfide peptide reference. Swallowed, orally disintegrating, and sublingual products should be recorded separately.
Collaborates with Biogen to discover and optimize oral macrocyclic peptides for immune diseases. Named targets, candidates, and human results have not been disclosed.
Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
Conducts multi-target oral macrocyclic peptide research with Unnatural Products. Evidence supporting marketed antibody products does not raise the evidence grade of the macrocycle program.
Entered chronic-disease macrocyclic peptide research through the Syneron Bio collaboration. No named clinical oral candidate from that collaboration has been disclosed.
Works with Orbis on oral macrocycle discovery and with Vivtex on delivery. Success with oral semaglutide does not automatically validate the collaborative macrocycle program.
SG6001 is an oral PCSK9 cyclic peptide. Official materials confirm a preclinical program and an out-licensing strategy; clinical status of other antifungal candidates is not applied to this program.
PL8177 is a colon-delivered cyclic heptapeptide MC1R agonist. The company reported Phase 2 UC proof of concept and explicitly welcomes partnerships / licensing.
Coverage expands from sourced records; this database does not claim all biopharma companies.
